Patrick Cooney, President of The Federal Group, was featured in Drug Topics to share his expertise on the likelihood of PBM legislation passing this year. In the article, Cooney examined the impact of the Federal Trade Commission’s (FTC) interim report in energizing lawmakers and shared his predictions on key provisions that might be included in the forthcoming legislation. His insights highlight the complexities of the legislative process and the significant implications for the pharmaceutical and healthcare industries.

Read the full article here: PBM Legislation Q&A.